STING1 and neoplasm: While DMXAA treatment did not significantly increase the frequency of CD103+ DCs within the tumor (data not shown), there was a profound and significant increase in CD86 expression on both CD103+ DCs and CD11b+ DCs in tumors treated with STING agonist.